The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Is Hydroxychloroquine Helpful for Patients with Antiphospholipid Syndrome?

Is Hydroxychloroquine Helpful for Patients with Antiphospholipid Syndrome?

December 17, 2018 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Patients with antiphospholipid syndrome (APS) also present with endothelial dysfunction, which can become thrombosis and early atheroma. Prior research has proposed the decreased dilation in APS patients may be the result of reduced nitric oxide bioavailability. The preservation of endothelial nitric oxide function requires, among other things, the bioavailability of tetrahydrobiopterin. Thus, tetrahydrobiopterin may be a key regulator of the balance between nitric oxide and reactive oxygen species.

You Might Also Like
  • Risk Assessment & Treatment in Antiphospholipid Syndrome Patients
  • New Assays May Help in the Diagnosis & Management of Antiphospholipid Syndrome
  • Antiphospholipid Syndrome
Also By This Author
  • Does Anti-Tumor Necrosis Factor-Alpha Increase Cardiovascular Burden?

To receive a diagnosis of APS, patients must test serologically positive for at least one of the following on two occasions 12 weeks apart: anticardiolipin antibodies, anti-beta-2-GPI antibodies (aB2GPI) and/or lupus anticoagulant. Of these, B2GPI may be the most relevant target of the antiphospholipid antibodies.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Physicians prescribe hydroxychloroquine to treat systemic lupus erythematosus (SLE), and it has been shown to have anti-thrombotic effects in SLE patients. Although obvious reasons exist to believe hydroxychloroquine may be useful to treat APS, its use in APS patients remains controversial. Those who argue for its use note that among hydroxychloroquine’s many mechanisms of action is its ability to inhibit aB2GPI binding to phospholipid bilayers.

Geoffrey Urbanski, MD, a doctor of internal medicine at Universite d’Angers, France, and colleagues hypothesized that hydroxychloroquine may reduce endothelial dysfunction in an APS animal model. Although most APS animal models create experimental thrombosis via mechanical, laser-induced or photochemical vascular injury, Dr. Urbanski and colleagues induced APS by injecting mice with a single dose of monoclonal antibody to B2GPI. This injection created endothelial dysfunction in mouse resistance arteries for three weeks. The investigators treated these APS mice with hydroxychloroquine, finding that the treatment improved endothelium-dependent dilation at three weeks. The research, published Nov. 6 in PloS One, also indicated that hydroxychloroquine can improve nitric oxide synthase coupling and reduce oxidative stress.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The investigators documented persistent impairment of both maximal vasodilation and sensitivity to acetylcholine for three weeks after the single injection of monoclonal aB2GPI as compared with untreated control mice. They also saw a reduction in both potency and sensitivity to acetylcholine in mice treated with the antibody. Because APS is more common in women than men, the researchers were surprised to find no differences in acetylcholine-mediated dilation between male and female mice. They also found responses to the endothelium independent dilator sodium nitroprusside (SNP) were not negatively affected by the antibody treatment. In fact, sensitivity to SNP was better in the antibody-treated mice than in the controls.

When the researchers treated the mice with hydroxychloroquine, they found the treatment improved acetylcholine-dependent dilation, but not maximal capacity. The restoration of dilation was large enough for the antibody-treated group to return to control levels. Additionally, the investigators found the addition of tetrahydrobiopterin and/or Tempol improved acetylcholine-mediated dilation in antibody-treated mice, but had no effect on the hydroxychloroquine-treated mice. This finding suggests that hydroxychloroquine likely reduces reactive oxygen species generation and, therefore, oxidative stress in the APS mouse model, an effect that is also seen when hydroxychloroquine is used to treat lupus.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: Antiphospholipid Antibody Syndrome (APS), Hughes Syndrome, HYDROXYCHLOROQUINE

You Might Also Like:
  • Risk Assessment & Treatment in Antiphospholipid Syndrome Patients
  • New Assays May Help in the Diagnosis & Management of Antiphospholipid Syndrome
  • Antiphospholipid Syndrome
  • Why Antiphospholipid Antibody Syndrome Should Be On Your Radar

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.